In a report released today, Alan Carr from Needham reiterated a Buy rating on Cara Therapeutics (CARA – Research Report), with a price target of $35.00. The company’s shares closed last Monday at $14.51.
According to TipRanks.com, Carr is a 3-star analyst with an average return of 2.3% and a 43.8% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Crispr Therapeutics AG, and Rhythm Pharmaceuticals.
Currently, the analyst consensus on Cara Therapeutics is a Strong Buy with an average price target of $29.00.
The company has a one-year high of $26.67 and a one-year low of $8.88. Currently, Cara Therapeutics has an average volume of 394.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.